These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26707008)

  • 1. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes.
    Hejlova I; Honsova E; Sticova E; Lanska V; Hucl T; Spicak J; Jirsa M; Trunecka P
    Liver Transpl; 2016 May; 22(5):644-55. PubMed ID: 26707008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation.
    Miyaaki H; Miuma S; Taura N; Shibata H; Sasaki R; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
    Transplantation; 2019 Jan; 103(1):109-112. PubMed ID: 29894414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
    Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil".
    Dumortier J; Giostra E; Belbouab S; Morard I; Guillaud O; Spahr L; Boillot O; Rubbia-Brandt L; Scoazec JY; Hadengue A
    Am J Gastroenterol; 2010 Mar; 105(3):613-20. PubMed ID: 20040915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.
    Brandman D; Pingitore A; Lai JC; Roberts JP; Ferrell L; Bass NM; Terrault NA
    Liver Transpl; 2011 Dec; 17(12):1380-6. PubMed ID: 21770018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation.
    Tokodai K; Karadagi A; Kjaernet F; Romano A; Ericzon BG; Nowak G
    Scand J Gastroenterol; 2019 Feb; 54(2):233-239. PubMed ID: 30999770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation.
    Narayanan P; Mara K; Izzy M; Dierkhising R; Heimbach J; Allen AM; Watt KD
    Transplantation; 2019 Jan; 103(1):e14-e21. PubMed ID: 29994981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study.
    Fukushima M; Miyaaki H; Sasaki R; Haraguchi M; Miuma S; Hara T; Soyama A; Hidaka M; Eguchi S; Nakao K
    Intern Med; 2023 May; 62(10):1415-1423. PubMed ID: 36171128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation.
    Kern B; Feurstein B; Fritz J; Fabritius C; Sucher R; Graziadei I; Bale R; Tilg H; Zoller H; Newsome P; Eschertzhuber S; Margreiter R; Öfner D; Schneeberger S
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):205-210. PubMed ID: 30320609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recipient But Not Donor Adiponectin Polymorphisms Are Associated With Early Posttransplant Hepatic Steatosis in Patients Transplanted for Non-Nonalcoholic Fatty Liver Disease Indications.
    John BV; Aiken T; Garber A; Thomas D; Lopez R; Patil D; Konjeti VR; Fung JJ; McCollough AJ; Askar M
    Exp Clin Transplant; 2018 Aug; 16(4):439-445. PubMed ID: 29863454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of liver transplantation in patients with prior bariatric surgery.
    Safwan M; Collins KM; Abouljoud MS; Salgia R
    Liver Transpl; 2017 Nov; 23(11):1415-1421. PubMed ID: 28752920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis.
    Vallin M; Guillaud O; Boillot O; Hervieu V; Scoazec JY; Dumortier J
    Liver Transpl; 2014 Sep; 20(9):1064-71. PubMed ID: 24961607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
    Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
    Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter.
    Chayanupatkul M; Dasani DB; Sogaard K; Schiano TD
    Transplant Proc; 2021; 53(1):159-165. PubMed ID: 32434740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese.
    Strey CBM; de Carli LA; Fantinelli M; Gobbato SS; Bassols GF; Losekann A; Coral GP
    Ann Hepatol; 2018 July - August ,; 17(4):585-591. PubMed ID: 29893699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between obesity after liver transplantation and steatosis, inflammation, and fibrosis of the graft.
    Dobrindt EM; Allex L; Saipbaev A; Öllinger R; Schöning W; Pratschke J; Eurich D
    Clin Transplant; 2020 Dec; 34(12):e14093. PubMed ID: 32970896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.
    Monto A; Alonzo J; Watson JJ; Grunfeld C; Wright TL
    Hepatology; 2002 Sep; 36(3):729-36. PubMed ID: 12198667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.